What explains the wide range of specialty drug rebates? New research from @mollytoba.bsky.social et al finds cancer/orphan drugs have the lowest rebates, and biosimilars/originators the highest.

Read more in Health Affairs Scholar at: tinyurl.com/y4rc468d

@argenx.com #PBM #Rebates #DrugPrices

1/ How closely do health plans’ drug #utilizationmanagement (UM) policies align with #clinicalguidelines? CEVR and NPC examined policies for 389 drug-indication pairs from 18 commercial insurers. Here’s a thread on what we found:

Strong @tuftscevr.bsky.social participation at #isporannual in Montreal! #ispor

Gearing up for a busy #ISPORAnnual for the @tuftscevr.bsky.social SPEC team! Come say hello, learn about our research and the SPEC database. #heor #marketaccess #healthpolicy

Come see CEVR's faculty and researchers share their work and insights at #ISPOR2025 in Montreal!

A list of our panels, workshops, poster presentations, and other activities can be found at tinyurl.com/mwy8yv3a

#ISPOR #HEOR #HealthPolicy

@tuftscevr.bsky.social Tufts CEVR annual meeting kicking off with an interview of Dariush Mozaffarian @foodismedicine.bsky.social discussing cardiometabolic health

Cancer drugs' average US net launch prices doubled from $100K to $200K between 2008 and 2022, with no clear link to clinical efficacy, raising questions about whether these prices reflect value.

Read new research co-authored by CEVR’s Katherine Clifford and James Chambers: tinyurl.com/4my6h8zs

US commercial and Medicare Advantage health plan coverage of anti-VEGF tx is frequently tighter than the FDA label. Plans require step therapy in up to 75% of policies; restrictions more frequent for originator drugs vs. biosimilars.

New from CEVR / Impact Education in JMCP: tinyurl.com/ydd783e4

From 2010 to 2016 (latest data I have ), NIH research contributed to EVERY drug approved by the FDA

The National Eczema Association awarded a Spotlight Research Grant to our #SPEC team to analyze US payer coverage policies for #atopicdermatitis tx. We will study coverage changes due to new evidence, tx, clinical guidelines; how disparities can cause health inequities.

tinyurl.com/33sbsdre

A great study led by my colleague Dan Enright highlighting the power of SPEC data. No only do we track coverage but also the evidence cited in coverage policies, enabling deeper insights into health plan decision making.

New study by my @tuftscevr.bsky.social colleague, Yolanda Zhu and colleagues.

The #IRA #Medicare Part D benefit redesign may significantly lower OOP drug spending for beneficiaries with #dementia and comorbidities.

tinyurl.com/5n8uxam3 #IRA #drugs

Grateful to Youth Enrichment Services Boston for the amazing ski experience for my tween! Let’s work to make skiing more accessible to all!

Don't miss an opportunity to work with our renowned faculty! Applications for our 2025 CEA Registry Summer Fellowship close March 17th.

Learn more / apply today: cevr.tuftsmedicalcenter.org/news/2025-ce...

#internships #fellowship #healthecon

@peterneumann11.bsky.social @pattysynnott.bsky.social